Thiabendazole (TBZ, Scheme 1) is a staple medicine for treating strongyloidiasis (threadworm), cutaneous and visceral larva migrans, trichinosis, and other parasites. The precise mode of action of the parasite is unknown, but it is believed to inhibit fumarate reductase and glucose transport and impede tubulin synthesis in parasitic species . Commercialized as MINTEZOL©, this drug is administered orally as tablets that should be chewed and kept in the mouth before swallowing or as a suspension. To mask the taste of the drug, sodium saccharinate, and other sweeteners are commonly added as excipients . The relatively low aqueous solubility of TBZ (28 mg/L in water) is a significant barrier to its effectiveness . Previous studies have attempted to increase TBZ solubility using prodrug design strategies, including N-acylation of the benzimidazole moiety of TBZ and ionic liquids . Other strategies include the formation of clay hybrids , salts , cosolvent blends , encapsulation in cyclodextrin , loading in silica , and others. While effective in increasing solubility, some of these approaches significantly increase production costs, hindering large-scale applications in developing countries' deworming programs.